RJA
RVMD icon

Raymond James & Associates’s Revolution Medicines RVMD Stock Holding History

Raymond James & Associates’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$225K – 4021
2023
Q4 		$225K Buy
+10,000
New +$240K ﹤0.01% 3454

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James & Associates's RVMD Position: Q3 2024 in Review

Raymond James & Associates increased its Revolution Medicines (RVMD) stake by 156% in Q3 2024, buying an estimated $5.06M and bringing the position to 190,505 shares worth $8.64M. The position accounts for 0.01% of the portfolio, ranked #1309.

Raymond James & Associates first reported a position in RVMD in Q4 2023 and has held it in 4 quarters since. 255 funds tracked by Wall St. Rank hold RVMD as of Q3 2024.

  • Raymond James & Associates held 190,505 shares of Revolution Medicines worth $8.64M as of Q3 2024.
  • Raymond James & Associates bought 116,135 Revolution Medicines shares in Q3 2024, an estimated $5.06M.
  • Revolution Medicines made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1309 holding.
  • Raymond James & Associates first reported a position in Revolution Medicines in Q4 2023 and has held it in 4 quarters since.
  • 255 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.